The international WAO/EAACI guideline for the management of hereditary angioedema - The 2017 revision and update

Marcus Maurer, Markus Magerl, Ignacio Ansotegui, Emel Aygören-Pürsün, Stephen Betschel, Konrad Bork, Tom Bowen, Henrik Balle Boysen, Henriette Farkas, Anete S. Grumach, Michihiro Hide, Constance Katelaris, Richard Lockey, Hilary Longhurst, William R. Lumry, Inmaculada Martinez-Saguer, Dumitru Moldovan, Alexander Nast, Ruby Pawankar, Paul PotterMarc Riedl, Bruce Ritchie, Lanny Rosenwasser, Mario Sánchez-Borges, Yuxiang Zhi, Bruce Zuraw, Timothy Craig

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Hereditary Angioedema (HAE) is a rare and disabling disease. Early diagnosis and appropriate therapy are essential. This update and revision of the global guideline for HAE provides up-to-date consensus recommendations for the management of HAE. In the development of this update and revision of the guideline, an international expert panel reviewed the existing evidence and developed 20 recommendations that were discussed, finalized and consented during the guideline consensus conference in June 2016 in Vienna. The final version of this update and revision of the guideline incorporates the contributions of a board of expert reviewers and the endorsing societies. The goal of this guideline update and revision is to provide clinicians and their patients with guidance that will assist them in making rational decisions in the management of HAE with deficient C1-inhibitor (type 1) and HAE with dysfunctional C1-inhibitor (type 2). The key clinical questions covered by these recommendations are: 1) How should HAE-1/2 be defined and classified?, 2) How should HAE-1/2 be diagnosed?, 3) Should HAE-1/2 patients receive prophylactic and/or on-demand treatment and what treatment options should be used?, 4) Should HAE-1/2 management be different for special HAE-1/2 patient groups such as pregnant/lactating women or children?, and 5) Should HAE-1/2 management incorporate self-administration of therapies and patient support measures? This article is co-published with permission in Allergy and the World Allergy Organization Journal.

Original languageEnglish (US)
Article number5
JournalWorld Allergy Organization Journal
Volume11
Issue number1
DOIs
StatePublished - Feb 27 2018

Fingerprint

Hereditary Angioedemas
Guidelines
Hereditary Angioedema Types I and II
Consensus
Self Administration
Therapeutics
Rare Diseases
Pregnant Women
Early Diagnosis
Decision Making
Hypersensitivity

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Pulmonary and Respiratory Medicine

Cite this

Maurer, Marcus ; Magerl, Markus ; Ansotegui, Ignacio ; Aygören-Pürsün, Emel ; Betschel, Stephen ; Bork, Konrad ; Bowen, Tom ; Boysen, Henrik Balle ; Farkas, Henriette ; Grumach, Anete S. ; Hide, Michihiro ; Katelaris, Constance ; Lockey, Richard ; Longhurst, Hilary ; Lumry, William R. ; Martinez-Saguer, Inmaculada ; Moldovan, Dumitru ; Nast, Alexander ; Pawankar, Ruby ; Potter, Paul ; Riedl, Marc ; Ritchie, Bruce ; Rosenwasser, Lanny ; Sánchez-Borges, Mario ; Zhi, Yuxiang ; Zuraw, Bruce ; Craig, Timothy. / The international WAO/EAACI guideline for the management of hereditary angioedema - The 2017 revision and update. In: World Allergy Organization Journal. 2018 ; Vol. 11, No. 1.
@article{e921fb2486ee4ad8a67f1ab03524d280,
title = "The international WAO/EAACI guideline for the management of hereditary angioedema - The 2017 revision and update",
abstract = "Hereditary Angioedema (HAE) is a rare and disabling disease. Early diagnosis and appropriate therapy are essential. This update and revision of the global guideline for HAE provides up-to-date consensus recommendations for the management of HAE. In the development of this update and revision of the guideline, an international expert panel reviewed the existing evidence and developed 20 recommendations that were discussed, finalized and consented during the guideline consensus conference in June 2016 in Vienna. The final version of this update and revision of the guideline incorporates the contributions of a board of expert reviewers and the endorsing societies. The goal of this guideline update and revision is to provide clinicians and their patients with guidance that will assist them in making rational decisions in the management of HAE with deficient C1-inhibitor (type 1) and HAE with dysfunctional C1-inhibitor (type 2). The key clinical questions covered by these recommendations are: 1) How should HAE-1/2 be defined and classified?, 2) How should HAE-1/2 be diagnosed?, 3) Should HAE-1/2 patients receive prophylactic and/or on-demand treatment and what treatment options should be used?, 4) Should HAE-1/2 management be different for special HAE-1/2 patient groups such as pregnant/lactating women or children?, and 5) Should HAE-1/2 management incorporate self-administration of therapies and patient support measures? This article is co-published with permission in Allergy and the World Allergy Organization Journal.",
author = "Marcus Maurer and Markus Magerl and Ignacio Ansotegui and Emel Ayg{\"o}ren-P{\"u}rs{\"u}n and Stephen Betschel and Konrad Bork and Tom Bowen and Boysen, {Henrik Balle} and Henriette Farkas and Grumach, {Anete S.} and Michihiro Hide and Constance Katelaris and Richard Lockey and Hilary Longhurst and Lumry, {William R.} and Inmaculada Martinez-Saguer and Dumitru Moldovan and Alexander Nast and Ruby Pawankar and Paul Potter and Marc Riedl and Bruce Ritchie and Lanny Rosenwasser and Mario S{\'a}nchez-Borges and Yuxiang Zhi and Bruce Zuraw and Timothy Craig",
year = "2018",
month = "2",
day = "27",
doi = "10.1186/s40413-017-0180-1",
language = "English (US)",
volume = "11",
journal = "World Allergy Organization Journal",
issn = "1939-4551",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

Maurer, M, Magerl, M, Ansotegui, I, Aygören-Pürsün, E, Betschel, S, Bork, K, Bowen, T, Boysen, HB, Farkas, H, Grumach, AS, Hide, M, Katelaris, C, Lockey, R, Longhurst, H, Lumry, WR, Martinez-Saguer, I, Moldovan, D, Nast, A, Pawankar, R, Potter, P, Riedl, M, Ritchie, B, Rosenwasser, L, Sánchez-Borges, M, Zhi, Y, Zuraw, B & Craig, T 2018, 'The international WAO/EAACI guideline for the management of hereditary angioedema - The 2017 revision and update', World Allergy Organization Journal, vol. 11, no. 1, 5. https://doi.org/10.1186/s40413-017-0180-1

The international WAO/EAACI guideline for the management of hereditary angioedema - The 2017 revision and update. / Maurer, Marcus; Magerl, Markus; Ansotegui, Ignacio; Aygören-Pürsün, Emel; Betschel, Stephen; Bork, Konrad; Bowen, Tom; Boysen, Henrik Balle; Farkas, Henriette; Grumach, Anete S.; Hide, Michihiro; Katelaris, Constance; Lockey, Richard; Longhurst, Hilary; Lumry, William R.; Martinez-Saguer, Inmaculada; Moldovan, Dumitru; Nast, Alexander; Pawankar, Ruby; Potter, Paul; Riedl, Marc; Ritchie, Bruce; Rosenwasser, Lanny; Sánchez-Borges, Mario; Zhi, Yuxiang; Zuraw, Bruce; Craig, Timothy.

In: World Allergy Organization Journal, Vol. 11, No. 1, 5, 27.02.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The international WAO/EAACI guideline for the management of hereditary angioedema - The 2017 revision and update

AU - Maurer, Marcus

AU - Magerl, Markus

AU - Ansotegui, Ignacio

AU - Aygören-Pürsün, Emel

AU - Betschel, Stephen

AU - Bork, Konrad

AU - Bowen, Tom

AU - Boysen, Henrik Balle

AU - Farkas, Henriette

AU - Grumach, Anete S.

AU - Hide, Michihiro

AU - Katelaris, Constance

AU - Lockey, Richard

AU - Longhurst, Hilary

AU - Lumry, William R.

AU - Martinez-Saguer, Inmaculada

AU - Moldovan, Dumitru

AU - Nast, Alexander

AU - Pawankar, Ruby

AU - Potter, Paul

AU - Riedl, Marc

AU - Ritchie, Bruce

AU - Rosenwasser, Lanny

AU - Sánchez-Borges, Mario

AU - Zhi, Yuxiang

AU - Zuraw, Bruce

AU - Craig, Timothy

PY - 2018/2/27

Y1 - 2018/2/27

N2 - Hereditary Angioedema (HAE) is a rare and disabling disease. Early diagnosis and appropriate therapy are essential. This update and revision of the global guideline for HAE provides up-to-date consensus recommendations for the management of HAE. In the development of this update and revision of the guideline, an international expert panel reviewed the existing evidence and developed 20 recommendations that were discussed, finalized and consented during the guideline consensus conference in June 2016 in Vienna. The final version of this update and revision of the guideline incorporates the contributions of a board of expert reviewers and the endorsing societies. The goal of this guideline update and revision is to provide clinicians and their patients with guidance that will assist them in making rational decisions in the management of HAE with deficient C1-inhibitor (type 1) and HAE with dysfunctional C1-inhibitor (type 2). The key clinical questions covered by these recommendations are: 1) How should HAE-1/2 be defined and classified?, 2) How should HAE-1/2 be diagnosed?, 3) Should HAE-1/2 patients receive prophylactic and/or on-demand treatment and what treatment options should be used?, 4) Should HAE-1/2 management be different for special HAE-1/2 patient groups such as pregnant/lactating women or children?, and 5) Should HAE-1/2 management incorporate self-administration of therapies and patient support measures? This article is co-published with permission in Allergy and the World Allergy Organization Journal.

AB - Hereditary Angioedema (HAE) is a rare and disabling disease. Early diagnosis and appropriate therapy are essential. This update and revision of the global guideline for HAE provides up-to-date consensus recommendations for the management of HAE. In the development of this update and revision of the guideline, an international expert panel reviewed the existing evidence and developed 20 recommendations that were discussed, finalized and consented during the guideline consensus conference in June 2016 in Vienna. The final version of this update and revision of the guideline incorporates the contributions of a board of expert reviewers and the endorsing societies. The goal of this guideline update and revision is to provide clinicians and their patients with guidance that will assist them in making rational decisions in the management of HAE with deficient C1-inhibitor (type 1) and HAE with dysfunctional C1-inhibitor (type 2). The key clinical questions covered by these recommendations are: 1) How should HAE-1/2 be defined and classified?, 2) How should HAE-1/2 be diagnosed?, 3) Should HAE-1/2 patients receive prophylactic and/or on-demand treatment and what treatment options should be used?, 4) Should HAE-1/2 management be different for special HAE-1/2 patient groups such as pregnant/lactating women or children?, and 5) Should HAE-1/2 management incorporate self-administration of therapies and patient support measures? This article is co-published with permission in Allergy and the World Allergy Organization Journal.

UR - http://www.scopus.com/inward/record.url?scp=85042715589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042715589&partnerID=8YFLogxK

U2 - 10.1186/s40413-017-0180-1

DO - 10.1186/s40413-017-0180-1

M3 - Article

AN - SCOPUS:85042715589

VL - 11

JO - World Allergy Organization Journal

JF - World Allergy Organization Journal

SN - 1939-4551

IS - 1

M1 - 5

ER -